DADC
HRTX icon

D.A. Davidson & Co’s Heron Therapeutics HRTX Stock Holding History

D.A. Davidson & Co’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,500
Closed -$17K – 1563
2025
Q3 		$17K Sell
13,500
-18,000
-57% -$28.5K ﹤0.01% 1513
2025
Q2 		$65.2K Hold
31,500
– – ﹤0.01% 1417
2025
Q1 		$69.3K Sell
31,500
-5,500
-15% -$10.7K ﹤0.01% 1376
2024
Q4 		$56.6K Sell
37,000
-176,630
-83% -$286K ﹤0.01% 1390
2024
Q3 		$425K Sell
213,630
-4,900
-2% -$11.7K ﹤0.01% 1075
2024
Q2 		$765K Buy
218,530
+47,530
+28% +$146K 0.01% 826
2024
Q1 		$474K Buy
171,000
+140,900
+468% +$354K ﹤0.01% 1009
2023
Q4 		$51.2K Sell
30,100
-10,500
-26% -$11.6K ﹤0.01% 1337
2023
Q3 		$41.8K Sell
40,600
-215,807
-84% -$307K ﹤0.01% 1301
2023
Q2 		$297K Buy
256,407
+34,962
+16% +$62.4K ﹤0.01% 1101
2023
Q1 		$334K Buy
221,445
+47,650
+27% +$119K ﹤0.01% 1039
2022
Q4 		$434K Sell
173,795
-22,982
-12% -$74K 0.01% 897
2022
Q3 		$830K Sell
196,777
-21,541
-10% -$84.3K 0.01% 649
2022
Q2 		$609K Sell
218,318
-3,824
-2% -$15.4K 0.01% 758
2022
Q1 		$1.27M Buy
222,142
+18,680
+9% +$137K 0.01% 577
2021
Q4 		$1.86M Buy
203,462
+32,760
+19% +$334K 0.02% 479
2021
Q3 		$1.82M Buy
170,702
+3,026
+2% +$36.8K 0.02% 453
2021
Q2 		$2.6M Buy
167,676
+44,879
+37% +$714K 0.03% 375
2021
Q1 		$1.99M Buy
122,797
+34,336
+39% +$612K 0.03% 405
2020
Q4 		$1.87M Buy
88,461
+8,032
+10% +$140K 0.03% 360
2020
Q3 		$1.19M Buy
80,429
+1,710
+2% +$26.7K 0.02% 410
2020
Q2 		$1.16M Buy
78,719
+46,752
+146% +$768K 0.02% 415
2020
Q1 		$375K Buy
+31,967
New +$601K 0.01% 661
2016
Q1 		– Sell
-100
Closed -$2K – 2296
2015
Q4 		$2K Buy
+100
New +$2.67K ﹤0.01% 2131
2015
Q3 		– Sell
-500
Closed -$15K – 2228
2015
Q2 		$15K Buy
+500
New +$9.41K ﹤0.01% 1766

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

D.A. Davidson & Co's HRTX Position: Q4 2025 in Review

D.A. Davidson & Co sold out of Heron Therapeutics (HRTX) in Q4 2025, closing a stake of 13,500 shares — an estimated $17K sold.

D.A. Davidson & Co first reported a position in HRTX in Q2 2015 and held it in 25 quarters. The position peaked at $2.6M in Q2 2021. 170 funds tracked by Wall St. Rank hold HRTX as of Q4 2025.

  • D.A. Davidson & Co reported no remaining Heron Therapeutics position as of Q4 2025 after selling out during the quarter.
  • D.A. Davidson & Co sold 13,500 Heron Therapeutics shares in Q4 2025, an estimated $17K.
  • D.A. Davidson & Co first reported a position in Heron Therapeutics in Q2 2015 and held it in 25 quarters.
  • D.A. Davidson & Co's Heron Therapeutics position peaked at $2.6M in Q2 2021.
  • 170 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2025.

Based on D.A. Davidson & Co's 13F filing for Q4 2025, filed 29 Jan 2026.